Cargando…
Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer
Development of novel multimodality radiotherapy treatments in metastatic breast cancer, especially in the most aggressive triple negative (TNBC) subtype, is of significant clinical interest. Here we show that a novel inhibitor of Polo-Like Kinase 4 (PLK4), CFI-400945, in combination with radiation,...
Autores principales: | Parsyan, Armen, Cruickshank, Jennifer, Hodgson, Kelsey, Wakeham, Drew, Pellizzari, Sierra, Bhat, Vasudeva, Cescon, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079282/ https://www.ncbi.nlm.nih.gov/pubmed/33866248 http://dx.doi.org/10.1016/j.breast.2021.03.011 |
Ejemplares similares
-
Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing’s sarcoma cells
por: Kerschner-Morales, Sophie L., et al.
Publicado: (2020) -
Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts
por: Lohse, Ines, et al.
Publicado: (2016) -
Polo-like kinase 4 inhibitor CFI-400945 inhibits carotid arterial neointima formation but increases atherosclerosis
por: Sun, Jiaxing, et al.
Publicado: (2023) -
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial
por: Veitch, Zachary W., et al.
Publicado: (2019) -
Role of Polo-like Kinases Plk1 and Plk4 in the Initiation of Centriole Duplication—Impact on Cancer
por: Hoffmann, Ingrid
Publicado: (2022)